As biologics and advanced therapies—including proteins, antibodies, and ATMPs—reshape the therapeutic landscape, the key challenge is no longer only scientific, but industrial. This roundtable will explore how CDMOs are evolving beyond isolated capabilities into integrated, platform-driven ecosystems that accelerate development, reduce risk, and enable efficient path-to-patient.
Rather than focusing solely on technologies, the discussion will highlight how collaboration across specialized players—viral vector developers, biologics manufacturers, and fill-finish experts—can create seamless development pathways. The goal is to understand how to connect early innovation with robust, scalable, and compliant manufacturing strategies.
Key Discussion Topics
- Platforms as enablers: How standardized platforms can reduce timelines and costs, while balancing the need for flexibility in complex and novel therapies.
- End-to-end thinking: The importance of integrating drug substance and drug product considerations early to avoid late-stage challenges.
- Scaling advanced therapies: Key bottlenecks in moving from clinical to commercial manufacturing, particularly for ATMPs and viral vectors.
- The power of proximity: Why close collaboration between CDMO teams and developers is critical to accelerate decision-making, knowledge transfer, and execution.
Differentiation Angle:
This session will provide a strategic perspective on how to move from fragmented innovation to coordinated industrial execution—combining platform efficiency with collaboration—to ultimately deliver complex therapies to patients faster and more reliably.
